Safety
heart failure
ACUTE MYOCARDIAL INFARCTION, ADVERSE EVENTS, UNSTABLE ANGINA, EVENTS, HEART FAILURE
The frequency of cardiovascular events was compared between the groups. The frequency of the predefined composite endpoint comprising cardiovascular mortality, acute myocardial infarction, unstable angina, and heart failure was significantly lower in the tofogliflozin group than in the conventional treatment group in the log-rank test (Additional file The adverse events (AEs) that occurred during the study are listed in Additional file 